Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology (Nasdaq: KURA) announced the initiation of its KOMET-001 Phase 2 trial for ziftomenib, a novel menin inhibitor targeting NPM1-mutant relapsed or refractory acute myeloid leukemia (AML). This follows promising Phase 1 results, which showed a 30% complete response rate among 20 patients at the recommended dosage of 600 mg. The Phase 2 trial aims to enroll 85 patients across the U.S. and Europe, focusing on complete response and safety as primary endpoints. Ziftomenib has received Orphan Drug Designation from the FDA, underscoring its potential in addressing the high unmet needs of AML patients with NPM1 mutations.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer therapies, announced its participation in the virtual SVB Securities Global Biopharma Conference. CEO Troy Wilson will engage in a fireside chat at 5:00 p.m. ET on February 14, 2023. A live audio webcast will be accessible on Kura's website, with an archived replay available thereafter. Kura's pipeline includes Ziftomenib for acute myeloid leukemia and Tipifarnib, which has received Breakthrough Therapy Designation for HRAS-mutant head and neck squamous cell carcinoma. Kura is also advancing KO-2806 through early clinical studies.
Kura Oncology (Nasdaq: KURA) announced that the FDA has cleared its Investigational New Drug (IND) application for KO-2806, a next-generation farnesyl transferase inhibitor (FTI) aimed at treating advanced solid tumors. The company plans to conduct a Phase 1 first-in-human study to assess the safety, tolerability, and preliminary antitumor activity of KO-2806, both as a monotherapy and in combination with other therapies. Kura aims to start this trial in Q3 2023, with KO-2806 designed to enhance the efficacy of earlier FTI candidates and address drug resistance in cancer treatments. The IND clearance is a pivotal step in expanding Kura's clinical pipeline.
Kura Oncology announced promising results from its KOMET-001 Phase 1/2 trial of ziftomenib for NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML). The trial showed a 30% complete remission (CR) rate at a 600 mg dose among 20 NPM1-mutant patients, with a low 5% rate of Grade 3 differentiation syndrome. The FDA has recommended 600 mg as the Phase 2 dose. Kura plans to initiate a registration-directed trial in Q1 2023 and explore combination therapies. These results highlight ziftomenib's potential as a promising treatment in a patient population with significant unmet needs.
Kura Oncology has announced an investor event on December 10, 2022, at 11:15 a.m. CT, following an oral presentation of data from the KOMET-001 trial at the ASH Annual Meeting in New Orleans. This event will feature insights from Kura's management and investigators on ziftomenib, a selective menin inhibitor, currently in Phase 1/2 trials targeting acute myeloid leukemia. Attendees can register for the live webcast on Kura's website, with an archived replay available afterwards.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that its CEO, Troy Wilson, will participate in two investor conferences. The first is a fireside chat at the Evercore ISI HealthCONx Conference on November 29, 2022, at 12:35 p.m. ET. The second is at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 12:20 p.m. ET. Audio webcasts will be available on Kura's website with archived replays after each event. Kura focuses on precision cancer medicines, with candidates like Ziftomenib in clinical trials.
Kura Oncology (Nasdaq: KURA) has announced that four abstracts concerning ziftomenib, a selective menin inhibitor, have been accepted for presentation at the ASH Annual Meeting on December 10-13, 2022, in New Orleans. Notable is the oral presentation of updated data from the KOMET-001 trial on ziftomenib for treating relapsed/refractory acute myeloid leukemia (AML). These presentations aim to showcase ziftomenib's potential impact on patient outcomes within this critical unmet need.
Kura Oncology reported third quarter 2022 results, highlighting the acceptance of updated KOMET-001 trial data for oral presentation at ASH. The company secured a $25 million equity investment from Bristol Myers Squibb and a $125 million term loan from Hercules Capital, extending financial runway into 2026. Key developments include positive preliminary results for tipifarnib plus alpelisib in HNSCC and the closure of AIM-HN trial to further enrollment. The net loss for Q3 2022 was $35.5 million, with R&D expenses rising to $25 million.
Kura Oncology (Nasdaq: KURA) announced a $25 million equity investment from Bristol Myers Squibb at $18.25 per share and a term loan facility of up to $125 million from Hercules Capital. The funds will support Kura's operations into 2026 if fully drawn. The loan includes an immediate draw of $10 million and potential additional tranches tied to clinical milestones. This collaboration aims to advance Kura's cancer treatments, enhancing their financial strength and strategic development capabilities.
Kura Oncology, Inc. (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two investor conferences. The first is a fireside chat at the Credit Suisse Healthcare Conference on November 9, 2022, at 1:25 p.m. ET in Ranch Palos Verdes, CA. The second will be at the Jefferies Global Healthcare Conference in London on November 16, 2022, at 3:15 p.m. GMT. Audio webcasts of both events will be available on Kura's website, along with archived replays.
Kura Oncology focuses on precision medicines for cancer treatment, with several clinical trials ongoing, including for ziftomenib and tipifarnib.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
